Enterprise Value
39.95M
Cash
70.58M
Avg Qtr Burn
-17.07M
Short % of Float
9.62%
Insider Ownership
1.51%
Institutional Own.
24.21%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NeoCart® (Autologous chondrocyte-derived neocartilage) Details Articular cartilage defects in the knee | Phase 3 Initiation | |
OCU400 Details Retinitis Pigmentosa | Phase 3 Initiation | |
COVAXIN (BBV152) Details COVID-19, Infectious disease | Phase 2/3 Update | |
OCU410ST Details Stargardt disease, Rare genetic disease | Phase 1/2 Initiation | |
OCU410 Details Geographic atrophy | Phase 1/2 Initiation |